Trust signals
Written by the FormBlends Medical Team. No peptide brand partnerships. All claims graded by evidence type. Last reviewed 2026-05-29.Key Takeaways
- Semaglutide (a GLP-1 peptide) produced 14.9% mean body weight loss vs. 2.4% placebo in the STEP-1 RCT of 1,961 adults, the strongest fat-loss peptide trial on record.
- Tesamorelin is the only GHRH-class peptide FDA-approved for fat reduction, cutting visceral adipose tissue by roughly 15 to 18% in HIV lipodystrophy RCTs.
- CJC-1295 and ipamorelin raise GH pulse amplitude in humans, but no published RCT has directly measured fat-mass reduction from either compound alone.
- AOD-9604 completed Phase IIb trials with modest signal, but Phase III did not confirm benefit for obesity and the program was halted.
- Stability matters as much as dose: reconstituted peptide solutions degrade at refrigerator temperature over days to weeks, meaning degraded stock can silently undermine any fat-loss protocol.
What are the best peptides for fat burning?
The best peptides for fat burning, ranked by human evidence, are semaglutide and tirzepatide (GLP-1/GIP receptor agonists with multiple large RCTs), tesamorelin (FDA-approved GHRH analog with visceral fat RCT data), and ipamorelin or CJC-1295 (mechanistic GH-secretion data only, no direct fat-loss RCT). Evidence quality drops sharply after the first two.Table of Contents
- Evidence ledger: every major claim graded
- How do GLP-1 peptides cause fat loss?
- Do GH-releasing peptides (CJC-1295, ipamorelin) actually burn fat?
- What is AOD-9604 and what happened in the trials?
- What most pages get wrong about peptides and fat burning
- Why stability and formulation matter more than dose
- Honest head-to-head: peptides vs. approved alternatives
- How to read a peptide COA and dose correctly
- What are the real safety concerns?
- FAQ
- Sources
Evidence ledger: every major claim graded
| Claim | Best Evidence Type | Key Data Point | Effect Direction | Confidence |
|---|---|---|---|---|
| Semaglutide reduces body weight | Human Phase III RCT (STEP-1, n=1,961) | 14.9% mean weight loss vs. 2.4% placebo over 68 weeks | Strong reduction | High |
| Tirzepatide reduces body weight | Human Phase III RCT (SURMOUNT-1, n=2,539) | Up to 22.5% mean weight loss at highest dose vs. 2.4% placebo | Strong reduction | High |
| Tesamorelin reduces visceral fat | Human RCT (multiple, HIV lipodystrophy) | Roughly 15 to 18% VAT reduction in Falutz et al. trials | Moderate reduction (visceral only) | High (in indicated population) |
| CJC-1295 raises GH and IGF-1 | Human PK/PD study (Teichman et al., 2006, n=21) | Dose-dependent GH increase; IGF-1 elevated by roughly 2-fold at higher doses | GH/IGF-1 increase confirmed | Moderate |
| CJC-1295 reduces fat mass | Mechanism extrapolation only | No direct human fat-loss RCT published | Speculative | Very Low |
| Ipamorelin raises GH in humans | Human PK study (Johansen et al., 1999) | GH pulse stimulated; selective for GH vs. cortisol/prolactin | GH increase | Moderate |
| Ipamorelin reduces fat mass | Mechanism extrapolation only | No published human fat-loss RCT | Speculative | Very Low |
| AOD-9604 produces fat loss | Phase IIb RCT (Heffernan et al., published data) | Modest signal in Phase IIb; Phase III did not confirm | Weak, not confirmed | Low |
| GH stimulates lipolysis | Human mechanistic studies (multiple) | GH activates hormone-sensitive lipase; effect established in GH-deficient patients | Lipolysis increase | Moderate (in deficient populations) |
How do GLP-1 peptides cause fat loss?
Semaglutide is a 31-amino-acid GLP-1 analog with a C-18 fatty acid chain that extends its half-life to roughly 7 days by enabling albumin binding and reducing renal clearance. Tirzepatide is a 39-amino-acid dual agonist hitting both GLP-1R and GIPR. Both are administered subcutaneously weekly.
Check your GLP-1 eligibility
Use our free BMI Calculator to see if you may qualify for provider-reviewed GLP-1 therapy.
Try the BMI Calculator →The fat-loss mechanism is primarily indirect. GLP-1 receptors in the hypothalamic arcuate nucleus reduce appetite signaling. Slowed gastric emptying extends satiety after meals. The STEP-1 trial (Wilding et al., NEJM 2021) showed participants reduced caloric intake substantially, and the weight lost was roughly two-thirds fat mass and one-third lean mass on DEXA in sub-studies. GLP-1 peptides do not directly stimulate adipocyte lipolysis in a clinically meaningful way at therapeutic doses. The fat loss is almost entirely downstream of a sustained caloric deficit.
What this does NOT prove: that the mechanism will transfer to any other peptide class, or that short-acting GLP-1 mimetics will produce the same results as weekly formulations with half-lives engineered for sustained receptor occupancy.
Do GH-releasing peptides (CJC-1295, ipamorelin) actually burn fat?
CJC-1295 is a GHRH analog with a drug affinity complex (DAC) modification that covalently binds albumin, extending its half-life from minutes to days. Teichman et al. (2006, J Clin Endocrinol Metab, n=21 healthy adults) showed dose-dependent GH and IGF-1 elevation, with IGF-1 roughly doubling at 60 mcg/kg and staying elevated for up to 14 days. That is the key pharmacology publication for CJC-1295-DAC.
Ipamorelin is a ghrelin receptor (GHS-R1a) agonist. Johansen et al. (1999) established that it stimulates GH release with high selectivity, meaning it does not substantially raise cortisol or prolactin unlike older secretagogues such as GHRP-6.
The logic for fat loss runs: elevated GH activates hormone-sensitive lipase in adipocytes, increasing free fatty acid release. This is real in GH-deficient patients, where GH replacement measurably reduces visceral fat over months. The honest caveat is that healthy adults with normal GH levels show a much blunted lipolytic response to additional GH, and the size of any fat-loss effect from CJC-1295 or ipamorelin in eugonadal, non-deficient adults has never been established in a powered RCT. Anyone citing specific fat-loss percentages for these compounds in healthy people is extrapolating, not quoting trial data.
What is AOD-9604 and what happened in the trials?
AOD-9604 corresponds to residues 176 to 191 of human growth hormone, a fragment that includes the region proposed to interact with beta-3 adrenergic receptors on adipocytes to stimulate lipolysis without binding IGF-1R or causing IGF-1 elevation. In vitro and animal studies showed promising lipolytic activity.
Metabolic Pharmaceuticals ran clinical trials. Phase IIb data showed a statistically modest signal for weight reduction vs. placebo at oral doses. Phase III trials did not replicate a significant effect, and the program was discontinued for obesity. The compound received GRAS (Generally Recognized as Safe) status from the FDA for food use, but it is not approved as an obesity drug. Most current online promotion of AOD-9604 for fat burning relies on the Phase IIb signal and ignores the Phase III failure. That is a material omission.
What most pages get wrong about peptides and fat burning
This is the section most listicles skip entirely.
Conflating mechanism with outcome. Raising GH, activating GHS-R1a, or stimulating beta-3 adrenergic receptors in a cell culture does not mean you will lose measurable fat in a real person eating ad libitum. The gap between mechanistic target engagement and clinical fat loss is enormous, and most pages present mechanism as if it were an outcome.
Ignoring bioavailability after subcutaneous injection. Most small peptides (under roughly 2,000 Da) are bioavailable subcutaneously, but absorption varies with injection site, adipose thickness, formulation pH, and aggregation state. Larger peptides or poorly formulated solutions can show bioavailability variability of 30 to 50% between individuals and even injection events. Research-grade materials frequently lack the excipient optimization of pharmaceutical products.
Purity reality. Research-grade peptides sold outside a pharmaceutical supply chain commonly show purity variation in independent testing. A compound labeled 98% pure may contain oxidized or truncated peptide fragments that are biologically inert or, in some cases, have unknown activity. No large supplier audit of research-grade CJC-1295 or ipamorelin batches has been published.
Caloric context is never mentioned. Every single fat-loss result in every peptide trial happened in the context of a caloric environment. Semaglutide's STEP-1 participants were counseled on a 500 kcal deficit diet and exercise. Attributing all fat loss to the peptide alone overstates its contribution.
Why stability and formulation matter more than dose
Peptides are susceptible to two main degradation pathways: hydrolysis (cleavage of peptide bonds by water, accelerated by heat and pH extremes) and oxidation (methionine, cysteine, and tryptophan residues are especially vulnerable). These are not hypothetical; they are the reason pharmaceutical peptide products specify storage conditions precisely.
Lyophilized (freeze-dried) powder is stable for months to over a year when stored below minus 20 degrees Celsius in darkness, because removing water nearly halts hydrolysis. Once reconstituted in bacteriostatic water, the clock starts. Semaglutide pharmaceutical pens are formulated with stabilizers (acetate buffer, propylene glycol, phenol) and are tested to maintain potency for weeks in refrigerator conditions. Research-grade reconstituted peptides lack those formulation optimizations.
What degraded peptide looks like: cloudiness or visible particulate in a previously clear solution is a failure sign. However, peptide degradation often produces no visible change; a solution can look identical while having lost a substantial fraction of active compound through hydrolysis. The only reliable check is mass spectrometry or HPLC, which most users do not have access to. This is why sourcing from vendors with third-party COA lot testing matters, and why the reconstituted vial should be used within a few days to one week rather than stored for months at refrigerator temperature.
The chemistry behind "store cold": at 4 degrees Celsius, hydrolysis rates are roughly 2 to 4 times slower than at 25 degrees Celsius for most peptides (consistent with Arrhenius kinetics), and oxidation slows significantly. Freezing reconstituted solutions is debated because freeze-thaw cycles can cause aggregation, reducing bioavailability. The practical rule is: reconstitute only what you need for a short period, keep refrigerated, and discard if storage extends beyond the vendor's stated post-reconstitution window.
Honest head-to-head: peptides vs. approved alternatives
| Agent | Best Evidence | Mean Fat/Weight Loss | Regulatory Status (US) | Peptide Wins | Peptide Loses |
|---|---|---|---|---|---|
| Semaglutide 2.4 mg weekly (Wegovy) | STEP-1 RCT, n=1,961 | ~14.9% body weight | FDA-approved (obesity) | Long half-life, once-weekly dosing | Cost, GI side effects, requires prescription |
| Tirzepatide 15 mg weekly (Zepbound) | SURMOUNT-1 RCT, n=2,539 | Up to ~22.5% body weight | FDA-approved (obesity) | Highest RCT weight loss on record for a peptide | Cost, nausea/vomiting in early titration |
| Tesamorelin 2 mg daily (Egrifta) | Multiple RCTs in HIV lipodystrophy | ~15-18% visceral fat only | FDA-approved (HIV lipodystrophy only) | Specific visceral fat reduction, preserves lean mass | Off-label for general obesity, daily injection, cost |
| CJC-1295 + Ipamorelin stack | Mechanistic PK studies only | Not established in RCT | Not approved, research compound | Preserves GH pulsatility, lower IGF-1 chronically vs. exogenous GH | No fat-loss RCT, purity risk, undefined safety long-term |
| AOD-9604 | Phase IIb signal, Phase III failure | Not clinically established | Not approved for obesity | No IGF-1 elevation | Phase III failed, development discontinued |
| Orlistat 120 mg TID (approved drug, non-peptide) | Multiple RCTs, meta-analyses | ~3-5% body weight vs. placebo | FDA-approved (obesity) | Oral, low cost, long safety record | Inferior weight loss vs. GLP-1 peptides, GI side effects |
The honest verdict: if the goal is maximum fat loss with the most robust evidence, semaglutide and tirzepatide are not even close comparisons for research peptides. CJC-1295 and ipamorelin are interesting for people with documented GH deficiency or in supervised anti-aging protocols where GH pulsatility is the goal, not as a primary obesity intervention.
How to read a peptide COA and dose correctly
Reading a COA (Certificate of Analysis). A credible COA specifies: the analytical method (HPLC-UV is minimum; mass spectrometry confirmation of molecular weight is better), the lot number, purity as a percentage of the stated peptide (not total powder weight, which includes excipients), and moisture content. Watch for COAs that report "peptide content" without specifying the method or that use a lot number that cannot be cross-referenced on the vendor's testing portal. A COA without a named third-party lab is a marketing document, not an analytical certificate.
Reconstitution math. Standard practice: add bacteriostatic water (0.9% benzyl alcohol) rather than sterile water, because benzyl alcohol inhibits bacterial growth over the use period. For a 5 mg vial: adding 2.5 mL gives 2 mg/mL (2,000 mcg/mL). Adding 5 mL gives 1 mg/mL (1,000 mcg/mL). To pull a 300 mcg dose from a 2 mg/mL solution: 300 divided by 2,000 equals 0.15 mL, drawn to the 15-unit mark on a 100-unit (1 mL) insulin syringe.
Dosing reference for studied compounds (based on published PK studies, not fat-loss RCTs).
| Peptide | Studied Dose Range | Route | Frequency in Studies | Evidence Base |
|---|---|---|---|---|
| Semaglutide (Wegovy) | 0.25 mg titrating to 2.4 mg | Subcutaneous | Once weekly | FDA-approved prescribing information |
| Tesamorelin (Egrifta) | 2 mg | Subcutaneous | Once daily | FDA-approved prescribing information |
| CJC-1295-DAC | 30 to 60 mcg/kg (Teichman 2006) | Subcutaneous | Once per 1 to 2 weeks (due to DAC half-life) | Single PK/PD study, n=21 |
| Ipamorelin | 200 to 300 mcg per dose (clinical practice) | Subcutaneous | 1 to 3 times daily | PK study extrapolation; no fat-loss RCT |
| AOD-9604 | 500 to 1,000 mcg (Phase II oral) | Subcutaneous or oral in trials | Once daily | Phase II trial data (Heffernan) |
What are the real safety concerns?
GLP-1 peptides (semaglutide, tirzepatide): Well-characterized. Most common adverse events are nausea, vomiting, and diarrhea, particularly during dose escalation. The FDA has issued a boxed warning about thyroid C-cell tumor risk (seen in rodents; human clinical significance unclear). Pancreatitis is a rare but documented risk. These compounds should only be used under physician supervision.
GH-secretagogues (CJC-1295, ipamorelin): Supraphysiologic GH over months raises IGF-1, which carries theoretical cancer promotion risk (the IGF-1 receptor is expressed on most cancer cell lines). Fluid retention and carpal tunnel symptoms are reported with GH excess. Insulin resistance can develop with sustained GH elevation. Long-term human safety data for these specific compounds at the doses used outside clinical trials does not exist.
AOD-9604: The available clinical trial data suggest a reasonable short-term safety profile. Its GRAS status for food use applies to the oral route at food additive levels, not to subcutaneous injection at pharmacological doses. Do not conflate these.
Sourcing risk: Research-grade peptides procured from unregulated suppliers have, in independent testing, sometimes contained heavy metal contamination, bacterial endotoxin above safe thresholds, or incorrect peptide sequences. This is not a theoretical risk. It is a documented reality of the unregulated supply chain.
FAQ
What are the best peptides for fat burning?
Semaglutide and tirzepatide lead on human RCT evidence, producing 15 to 22% body weight loss in large trials. Among research peptides, CJC-1295 with ipamorelin stacks GH secretion data but lacks direct fat-loss RCTs. AOD-9604 has modest human pilot data. Tesamorelin is FDA-approved specifically for visceral fat reduction in HIV lipodystrophy.
How do GLP-1 peptides cause fat loss?
GLP-1 receptor agonists slow gastric emptying, reduce appetite via hypothalamic GLP-1R signaling, and increase satiety signaling. They do not directly stimulate lipolysis; fat loss is almost entirely downstream of caloric deficit, not direct fat-cell action.
Does CJC-1295 actually burn fat?
CJC-1295 raises GH pulse amplitude and IGF-1 in humans, and GH promotes lipolysis via hormone-sensitive lipase activation. However, no large RCT has directly measured fat-mass reduction from CJC-1295 alone. Evidence for fat loss is mechanistic and extrapolated from GH replacement studies.
What is AOD-9604 and does it work for fat loss?
AOD-9604 is a synthetic fragment of GH (amino acids 176 to 191) that activates beta-3 adrenergic receptors to stimulate lipolysis in vitro. One small Phase IIb trial showed modest weight loss vs. placebo, but Phase III trials did not confirm a significant effect and development was discontinued for obesity.
Is tesamorelin better than CJC-1295 for fat loss?
Tesamorelin has a significant advantage: it is FDA-approved, has multiple RCTs in humans showing visceral fat reduction of roughly 15 to 18% in HIV lipodystrophy, and has defined pharmacokinetics. CJC-1295 has no comparable direct fat-loss RCT data. Tesamorelin wins on evidence quality.
How do I dose ipamorelin for fat loss?
Ipamorelin is typically studied at 200 to 300 mcg per injection subcutaneously, one to three times daily, to stimulate GH pulses. There is no large human RCT that has established an optimal dose specifically for fat loss. These doses come from smaller pharmacokinetic studies and clinical practice extrapolation.
What do most pages get wrong about peptides and fat burning?
Most pages conflate mechanism with outcome. A peptide raising GH or IGF-1 does not automatically produce measurable fat loss in a healthy person. Bioavailability after subcutaneous injection, purity of research-grade material, and caloric context all determine real-world results and are almost never discussed.
Are fat-burning peptides safe?
Safety profiles differ sharply by peptide. FDA-approved semaglutide and tesamorelin have documented safety data from large trials. Research peptides like CJC-1295 and ipamorelin have limited long-term human safety data. Common concerns include fluid retention, insulin resistance at high GH levels, and injection-site reactions.
Can you stack peptides for greater fat loss?
Stacking, for example CJC-1295 with ipamorelin, is practiced to combine GHRH and ghrelin-receptor mechanisms for larger GH pulses. There is pharmacological rationale for additive GH release, but no human RCT has tested a stack specifically for fat-loss outcomes or characterized combined safety.
How does peptide stability affect fat-burning results?
Peptides degrade via hydrolysis and oxidation. Lyophilized powder stored below minus 20 degrees Celsius is stable for months; reconstituted solution degrades meaningfully within days to weeks at refrigerator temperature. Using degraded peptide means receiving a fraction of the stated dose, directly undermining any fat-loss effect.
Do fat-burning peptides require a prescription?
In the United States, semaglutide, tirzepatide, and tesamorelin require a prescription. CJC-1295, ipamorelin, and AOD-9604 are sold as research chemicals and are not FDA-approved for human use. Using unapproved peptides for fat loss carries regulatory and safety risks.
Sources
- Wilding JPH, et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1). N Engl J Med. 2021;384(11):989-1002.
- Jastreboff AM, et al. Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1). N Engl J Med. 2022;387(3):205-216.
- Falutz J, et al. Metabolic effects of a growth hormone-releasing factor in patients with HIV. N Engl J Med. 2007;357(23):2359-2370.
- Teichman SL, et al. Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults. J Clin Endocrinol Metab. 2006;91(3):799-805.
- Johansen PB, et al. Ipamorelin, a new growth-hormone-releasing peptide, induces longitudinal bone growth in rats. Growth Horm IGF Res. 1999;9(2):106-113.
- Heffernan M, et al. The effects of human GH and its lipolytic fragment (AOD9604) on lipid metabolism following chronic treatment in obese mice and beta(3)-AR knockout mice. Endocrinology. 2001;142(12):5182-5189.
- Egrifta (tesamorelin) Prescribing Information. Theratechnologies Inc. FDA NDA 022505.
- Wegovy (semaglutide) Prescribing Information. Novo Nordisk. FDA NDA 215256.
- Zepbound (tirzepatide) Prescribing Information. Eli Lilly. FDA NDA 217806.
- Ho KY, et al. Fasting enhances growth hormone secretion and amplifies the complex rhythms of growth hormone secretion in man. J Clin Invest. 1988;81(4):968-975. (Mechanism basis for GH and lipolysis.)
Related peptide guides
Footer disclaimers
Platform: FormBlends is an informational platform. Content is written for educational purposes and does not constitute medical advice, diagnosis, or treatment recommendations.
Research Compounds: CJC-1295, ipamorelin, and AOD-9604 referenced on this page are not FDA-approved for human therapeutic use and are classified as research chemicals. They should not be self-administered outside a supervised clinical context.
Results: Individual results vary. Fat-loss figures cited are from specific clinical trials in specific populations and do not represent expected outcomes for any individual reader.
Trademarks: Wegovy is a registered trademark of Novo Nordisk. Zepbound is a registered trademark of Eli Lilly and Company. Egrifta is a registered trademark of Theratechnologies Inc. FormBlends has no affiliation with these companies.